| Trial ID: | L5260 |
| Source ID: | NCT00430742
|
| Associated Drug: |
Taranabant
|
| Title: |
An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Obesity Type 2 Diabetes Mellitus|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Taranabant|DRUG: Comparator: Placebo
|
| Outcome Measures: |
Primary: Body weight at 36 weeks, HbA1c at 36 weeks, 36 weeks | Secondary: Body weight at 24 and 52 weeks, HbA1c at 24 and 52 weeks, 24 and 52 weeks
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
600
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2006-11
|
| Completion Date: |
2008-11
|
| Results First Posted: |
|
| Last Update Posted: |
2015-02-13
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00430742
|
